Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36 mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

FoodBev caught up with Rafael Acevedo, Danone’s president of yogurt, to find out more about the rising trends behind the brand's new 'first-of-its-kind' innovation.

The product is viewed by the CPG giant as a “one-of-a-kind opportunity” to help consumers rebuild or maintain muscle they ...

Drivers of revenue growth included more customers using multiple chronic condition programs as well as strong adoption of GLP ...

Data reveals rising consumer interest across key areas including function-first wellness, science-backed self-care, and ...

A groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under ...

In today's video, I will look at four stocks that have seen meaningful pullbacks and now appear undervalued. In a stock ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...

This has turned into a three part look at GLP-1s. While writing my thoughts on GLP-1s, I thought that Dr Robert Cywes would be an excellent podcast guest on the topics of carb addiction, obesity and ...

Successful completion of strategic reorganization, reducing debt by $1.15 billion.In connection with emergence on 6/24/25, fiscal Q2 consists of a "Predecessor" period from 3/30/25 to 6/24/25, and a ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...